000			03470cam a2200421 i 4500
001			200442828
003			TR-AnTOB
005			20260105170952.0
008			150203s2014 cy a sb 000 0 eng d
020			_a9789963717064
035			_a(OCoLC)910948346
040			_aDNLM _beng _dDNLM _d20200114 _dWaSeSS _cTR-AnTOB _erda
041	0		_aeng
042			_apcc
060	0	0	_aWH 170
096			_bWH170 _e.G853 2014
245	0	0	_aGuidelines for the management of transfusion dependent thalassaemia (TDT) / _ceditors M.D. Cappellini [and four others].
250			_a3rd edition.
264		1	_aNicosia (CY) : _bThalassaemia International Federation, _c2014.
300			_a251 pages : _billustrations ; _c23 cm _eCD-ROM (4 3/4 in.)
336			_2rdacontent _atext _btxt
337			_2rdamedia _aunmediated _bn
338			_2rdacarrier _avolume _bnc
500			_aTitle from Bookshelf entry page.
520	3		_aThe full costs of treating patients with inherited disorders of haemoglobin is extremely variable among countries depending on different health care systems, varying methods of obtaining blood, different practices in screening for blood pathogens and different costs of drugs and equipment. It is evident that all countries would benefit from the sharing of experience and expertise in order to harmonize and optimize the quality of treatment as much as possible. The need for management guidelines for Transfusion Dependent Thalassaemias (TDT) is clear. Throughout the past four years, six major TDT management guidelines became available for use by thalassaemia care givers (TIF, US, Canadian, UK, Italian and Australian Guidelines). A comparison among those guidelines has been recently published (Musallam KM et al. Acta Haematologica 2013). In light of a swiftly evolving evidence, the need for revisiting and updating TDT management recommendations remains crucial. More importantly, ensuring access to such guidelines and careful application and implementation should only help arriving at early diagnosis of morbidity to allow prompt and effective management. It would also allow early prediction of risk and would enable preventive measures to be set in place saving unnecessary health care costs. This updated third edition of the TIF guidelines will offer valuable information to all allied healthcare professionals involved in the treatment of patients with TDT. It includes updated information on new approaches for more effective, safe and less laborious treatment, and an overview of the progress achieved to date towards a total cure using methods such as gene therapy and stem cell transplantation.
588			_aDescription based on version viewed May 1, 2015.
590			_aThis freely accessible collection of books may include only specific chapters of some books.
650	1	2	_aThalassemia _xtherapy _0https://id.nlm.nih.gov/mesh/D013789Q000628 _9151547
650	2	2	_aThalassemia _xcomplications _0https://id.nlm.nih.gov/mesh/D013789Q000150 _9151548
650	2	2	_aBlood Transfusion _0https://id.nlm.nih.gov/mesh/D001803. _9143167
650	2	2	_aInternationality _0https://id.nlm.nih.gov/mesh/D038622. _9151549
655		2	_aPractice Guideline _9143419
700	1		_aCappellini, Maria-Domenica _9132039
710	2		_aThalassaemia International Federation _9151476
856	4	0	_uhttps://www.ncbi.nlm.nih.gov/books/NBK269382 _zConnect to online resource via NCBI Bookshelf - All users
942			_2NLM _cBK
999			_c200442828 _d61040